A list of Texas companies to boycott in response to the deployment is catching steam. In what's being dubbed "the Governor Abbott Boycott," consumers are holding back from purchases with the most ...

Peter Marks, the former top vaccine regulator who was ousted from the U.S. Food and Drug Administration earlier this year, has joined Eli Lilly , the drugmaker told Reuters on Tuesday.

HHS Secretary Robert F. Kennedy Jr. is transferring dozens of public health corps officers to Indian Health Service centers amid severe staffing shortages.

Fintel reports that on October 8, 2025, Guggenheim maintained coverage of Eli Lilly and (NYSE:LLY) with a Buy recommendation. Analyst Price Forecast Suggests 7.19% Upside As of September 29, 2025, the ...

(Reuters) -Telehealth company HealthTap said on Wednesday it is joining Eli Lilly's digital healthcare platform, LillyDirect, to offer virtual diabetes management services. Diabetic patients across ...

Surge in demand and a shift towards higher dosage led to a 42 percent jump in sales of the weight-loss drug, the report said ...

According to PharmaTrac data for September 2025, Mounjaro clocked ₹80 crore in monthly sales - just behind GSK’s Augmentin at ₹85 crore and ahead of Pan at ₹77 crore - marking a sharp 43% ...

The former director of the FDA's Center for Biologics Evaluation and Research (CBER), Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.

Oracle (ORCL -2.43%) quietly transformed itself over the past couple of years from an aging database giant into a critical enabler of the global artificial intelligence (AI) infra ...

Eli Lilly & Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. Eli Lilly & Company (NYSE:LLY) gained attention on September 29 when ...

Erik Anderson has been elected vice chairman of Lumen Bioscience. Mary E. Brunkow, Fred Ramsdell and Dr. Shimon Sakaguchi won the Nobel Prize in Medicine for discoveries about how the immune system ...

Mounjaro has become India’s second-highest selling drug within six months of launch. Its rise highlights growing demand amid the country’s obesity and diabetes challenges.